Annotation of rs34231037

Genotype AG is associated with increased clinical benefit to sunitinib as compared to genotype GG.

Clinical benefit as defined by the comparison of CR (complete response), PR (partial response), SD (stable disease) > 1 year vs. PD (progressive disease), SD < 1 year.

From Publication

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and genomics. 2017. Apellániz-Ruiz María et al.
PMID:28430711(opens in new window) DOI:10.1097/FPC.0000000000000280(opens in new window)

Gene

KDR

Variant

rs34231037

Phenotype Category

Efficacy

Association Significance

The study reports this association is significant

PharmGKB ID

1448615381

Score
More info on scoring

2.5

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    cohort

    Study size

    246

    Association p-value

    = 0.047

    Statistical analysis

    OR: 3.78

    Confidence interval

    1.02 - 14.06

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    Loading...